Article
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Clinica chimica acta; international journal of clinical chemistry - 1 Nov 2006
Zhang Wei, Yu Bang-Ning, He Yi-Jing, Fan Lan, Li Qing, Liu Zhao-Qian, Wang An, Liu Ya-Li, Tan Zhi-Rong, Fen-Jiang, Huang Yuan-Fei, Zhou Hong-Hao
Abstract excerpt
BACKGROUND: Rosuvastatin, a novel potent HMG-CoA reductase inhibitor, is excreted into bile mediated by breast cancer resistance protein (BCRP). Our objective was to determine the association between the most frequent single nucleotide polymorphisms (SNPs) of the BCRP (421C>A) and the pharmacokinetics of rosuvastatin. METHOD: Pre-screening of SLCO1B1 521TC and CYP2C9*1/*3 were performed before this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
